ArticleBMC infectious diseases2026
Infectious adverse events in patients treated with biotherapies in a tropical Amazonian context, French Guiana.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on infectious complications associated with biologic therapies in tropical settings are scarce. French Guiana, an Amazonian French overseas territory, combines an important burden of infectious diseases with a high use of biologic therapies. Our objective was to assess the incidence, spectrum, and risk factors for infections in patients treated with biotherapies for inflammatory and autoimmune diseases in French Guiana.
methodsWe performed a multicentre retrospective study of adult patients receiving biotherapies between January 2021 and December 2023 in the French Guiana University Hospital (including its main site in Cayenne, its three local hospitals and 15 remote health centres). The primary outcome was the occurrence of any infectious event. Secondary outcomes included the severity of infection and identification of clinical and epidemiological risk factors.
results146 patients (mean age 44.1 years, 61.6% female) were included. 48.0% of patients included had at least one infectious event. Most infections were mild (90.4%) and significantly associated with concomitant immunosuppressants (35.7%) or with remote health centres follow-up (11.4%). The tropical context revealed a distinct epidemiology, with five cases of dengue fever, two cases of scabies and one histoplasmosis. The majority (55%) of events occurred under first-generation biotherapies (notably rituximab and anti-TNF agents). The most frequent type of infection was cutaneous (27.2%), particularly in patients with a dermatological indication.
conclusionsBiotherapies appear generally well tolerated in this tropical setting, but patients living in remote areas or with concomitant immunosuppressant therapies remain vulnerable. Specific awareness should be dedicated to secondary cutaneous infections in patients treated for dermatological indications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.